
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
New data from the Diabetes Prevention Outcomes Study shows persistent reduction of type 2 diabetes development over 22-year average follow-up.
Long-term follow-up of participants enrolled in the Diabetes Prevention Program Outcomes Study (DPPOS) demonstrates a significant and persistent reduction in risk for type 2 diabetes. The latest DPPOS results were presented at the American Diabetes Association 80th Virtual Scientific Sessions. The DPP/DPPOS is the largest and longest running diabetes prevention study that continues to actively follow participants.
In the short slide show below, find highlights from the symposium, “New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS).”





